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function by Lequesne Algofunctional Index, mobility by Timed Up and
Go Test (TUG), KROM by goniometry of knee ﬂexion and hamstring
shortening by popliteal angle. The statistical method followed the
principles of per-protocol analysis.
Results: On average, the participants’ age was 63.5 years, the BMI was
31.2 and 78.4% were women. All groups demonstrated a signiﬁcant
improvement in pain, total WOMAC, Lequesne and TUG following
treatment compared to control (both p<.001). Hamstring shortening
improved after the combined treatment (LLLT þ stretching) (p<.001).
The LLLTPLACEBO þ Stretch was the only group better than control in
improving KROM (p¼0.02). On average, there was a 50% improve-
ment in pain, 39% in total WOMAC, 30% in Lequesne and 20% in TUG
for all active treatment groups compared to a control. For the com-
bined treatment groups there was a 43% improvement in hamstring
length.
Conclusions: Our results suggest that LLLT and static stretching, com-
bined or as monotherapy, were effective in reducing pain and improv-
ing self-reported symptoms, mobility and function. Only the combined
treatment demonstrated improvements in hamstring shortening.Initial Assessment x Final Assessment
Groups Average gain Relative
gain
p
Average ± SD/ Median
[25%-75%]
VAS (0e10 cm) 1 3.2 ± 2.1 50.3% <0.001
2 3.8 ± 2.3 57.7%
3 3.1 ± 2.9 47.0%
4 3.3 ± 2.2 54.2%
5 0.7 ± 3.0 12.4%
WOMAC (0e96) 1 8.0 [6.0  15.0] 33.9% <0.001
2 11.0 [4.5  21.5] 38.9%
3 13.0 [5.7  22.5] 42.0%
4 16.0 [8.7  24.5] 41.4%
5 2.0 [ 2.5  8.5] 1.5%
LEQUESNE (0e24) 1 2.5 [0.4  5.1] 23.4% <0.001
2 1.5 [0.5  5.2] 25.8%
3 4.0 [0.5  6.6] 39.6%
4 3.5 [1.9  5.6] 31.5%
5 0.0 [2.2  1.0] -10.4%
TUG(s) 1 2.5 [0.2  4.7] 18.0% <0.001
2 3.0 [1.1  6.7] 23.1%
3 2.6 [1.3  4.1] 19.1%
4 3.1 [0.5  6.4] 19.9%
5 0.0 [1.0  1.2] -1.3%
KROM () 1 7.0 [3.0  15.0] 9.4% 0.02
2 10.0 [4.0  15.2] 12.0%
3 6.0 [1.0  11.5] 5.3%
4 10.0 [7.5  23.2] 8.5%
5 1.0 [5.5  7.0] 0.9%
Popliteal angle () 1 10.0 [1.0  15.0] 37.6% <0.001
2 12.0 [5.0  18.2] 47.9%
3 4.0 [1.2  8.7] 11.7%
4 0.0 [6.0  6.2] 1.2%
5 0.5 [4.5  4.0] 1.2%255
THE CURRENT STATUS OF IMAGING IN ANTI-NGF CLINICAL TRIALS
C.G. Miller y, A. Guermazi z, H. Yu y, F. Roemer x. yBioClinica, Newtown,
PA, USA; zBoston Univ. Sch. of Med., Boston, MA, USA; xUniv. of
Erlangen-Nuremberg, Erlangen, Germany
Purpose: Nerve Growth Factor (NGF) is a neurotrophin that regulates
the structure and function of responsive sensory neurons and is a
regulator of pain sensitivity and processing. The concept of targeting
NGF to target chronic pain syndromes has been gaining momentum
since 1990.
There have been a signiﬁcant number of trials conducted or being ini-
tiated. This abstract provides a review of the studies that have evaluated
a-NGF compounds.Methods: A thorough review was performed on the web site www.
clinicaltrials.gov to identify all a-NGF studies that have been con-
ducted. The terms anti-NGF, and a-NGF only return a limited number
of results so the individual compounds had to be identiﬁed either by
their generic name or compound number. 45 studies were identiﬁed
and although 2 studies had been withdrawn prior to randomization, a
total of 15,664 subjects have been enrolled in studies with the aNGF
mAbs. Seven of these trials have been published in peer-reviewed
journals.
Results: While the majority (26) of studies have been conducted by
Pﬁzer with Tanezumab, there have been 7 with Fulranumab previously
known as JNJ-42160443 (Johnson & Johnson Pharmaceutical Research
& Development), and 9 with Fasinumab previously known as REGN475
(Regeneron pharmaceuticals/Sanoﬁ). Many of the studies have been
either terminated (24), or completed (16) but there is one currently
active (not recruiting) in cancer-related pain (Fulranumab). There is also
a study of 450 subjects with OA of the knee and hips that is planned to
start recruiting in January 2014.
The number of indications that have been studied comprise of osteo-
arthritis (21), which includes either the knee, hip or both; low back pain
(4), and a variety of pain syndromes (11) including neuropathic pain
from diabetes (2), plus three in cancer pain of which one is on-going.
In the Tanezumab program 249 subjects were adjudicated for AEs
related to the joints. Of these 68 had Rapidly Progressing Osteoarthritis
(RPOA), 67 in the Phase III program and 1 in the Phase 1 program for
chronic back pain. The advisory board noted that 13 of the 68 subjects
had deﬁnite evidence of SIF at enrollment. This program had the largest
number of enrolled subjects at the time of FDA cessation of the program
(13310 subjects of the 15,664 enrolled in aNGF studies or 85%). While
these subjects were identiﬁed post hoc, SIF, RPOA and joint destruction
was not an AE that was anticipated a priori and therefore nothing pro-
actively built into the studies to evaluate the true incidence of these
events.
Conclusions: In summary, medical imaging and the thorough radio-
logical evaluation of the major articulating joints for all subjects in
future aNGF studies will be required. The ﬁrst step will be to rule out
possible pathology or those at high risk of going onto a catastrophic
joint failure. Then secondly to closely monitor the subjects during the
treatment phase with radiography and if inconclusive also with mag-
netic resonance imaging to ensure that any possible events will be
identiﬁed early and the subject managed to prevent any further bone or
joint damage.
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RADIOGRAPHIC AND MRI ASSESSMENT IN OSTEOARTHRITIS
EFFICACY STUDIES AND ANTI-NERVE GROWTH FACTOR PROGRAMS:
CHARACTERISTICS AND DIFFERENCES
A. Guermazi y, M. Hellio Le Graverand z, C. Miller x, C. West k,
M. Brown x, R. Clemmer x, F. Roemer y. yBoston Univ. Sch. of Med., Boston,
MA, USA; z Pﬁzer, Tokyo, Japan; xBioClinica, Princeton, NJ, USA; k Pﬁzer,
Groton, CT, USA
Purpose: The osteoarthritis (OA) research community has long-stand-
ing experience with studies assessing therapeutic efﬁcacy, which is
commonly deﬁned as slowing of joint space narrowing (JSN). Para-
mount for longitudinal radiologic evaluation of radiographs is opti-
mized image acquisition in a reliable fashion in order to guarantee
comparability between time points. Recently nerve growth factor
inhibitors (a-NGF) have been introduced for treatment of OA symptoms,
and have shown good analgesic efﬁcacy and improvement in function
in patients with OA. However, a-NGF trials in OAwere suspended due to
concerns over accelerated rates of OA progression. Since a-NGF thera-
pies offer potential as the ﬁrst new class of analgesics in many years,
future studies assessing a-NGF compounds will include stringent eli-
gibility criteria as risk mitigation measures and will require rigorous
safety monitoring during the studies. While disease-modifying effects
are not expected with a-NGF treatment, imaging is paramount to
identify potential negative outcomes as early as possible. These imaging
ﬁndings include atrophic OA, osteonecrosis and others at screening and
especially rapidly progressive OA Type I (i.e. rapid progression of JSN
>2mm/year) and II (i.e. abnormal loss of bone or bone destruction that
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A169does not normally occur in end-stage OA) during the course of
treatment.
The aim was to describe the core differences in regard to image
acquisition and radiologic assessment in OA efﬁcacy studies and studies
assessing a-NGF compounds.
Methods: The current standards in image acquisition and assess-
ment in OA efﬁcacy studies will be reviewed based on the authors’
long-standing involvement in OA trials and the available literature.
In particular, the role of radiography vs. MRI will be brieﬂy
reviewed. These ﬁndings will be contrasted to past and future a-
NGF studies applying radiography and MRI for patient eligibility
and safety monitoring. Differences between expected JSN in OA vs.
rapid progression will be discussed. In addition, the role of MRI as
an adjunct instrument to detect early ﬁndings of relevance will be
emphasized.
Results: In regard to eligibility, OA efﬁcacy studies require semi-
quantitative assessment of screening radiographs to deﬁne disease
severity. Similarly in a-NGF studies, subjects may be included based on
screening radiographs. In addition to standard semiquantitative
assessment, additional pre-deﬁned diagnoses of exclusion have to be
considered, such as atrophic OA, which potentially indicate increased
risk of more rapid progression. In regard to on-study radiologic
assessment, the focus in traditional OA efﬁcacy studies is on maximized
sensitivity to change over time to detect differences in JSN, while in a-
NGF studies the focus lies on maximized sensitivity to detect early
adverse ﬁndings that potentially result in withdrawal from treatment.
Especially in cases of discrepant clinical and radiographic ﬁndings
additional MRI examinations are needed to increase sensitivity to
detect early changes.
Fig. 1. Osteoarthritis efﬁcacy study. A. Baseline image shows medial joint
space narrowing (JSN) (arrows). B. At 2-year follow-up there is an increase
in JSN that is deﬁnite but does not suggest rapid progression
Fig 2. a-NGF study. A. Baseline image shows deﬁnite medial JSN (arrows)
and no osteophytes consistent with atrophic OA. B. At the 9-month fol-
low-up rapid progression in JSN is seen with now bone-to-bone appear-
ance (arrows). Finding is consistent with RPOA Type I.Fig 3. a-NGF study. A. Baseline image shows deﬁnite osteoarthritis
Kellgren-Lawrence Grade III with presence of osteophytes and medial JSN.
B. At the 12-month follow-up severe disintegration of the medial com-
partment including collapse of the tibial plateau is observed. Finding is
consistent with RPOA Type II.
Conclusions: The role of radiologic assessment differs in traditional
efﬁcacy and a-NGF studies. While in traditional efﬁcacy studies image
acquisition and evaluation is optimized for sensitivity to detect minor
changes between treated and non-treated subjects, in a-NGF studies the
focus is on early detection of diagnoses that either puts a subject at
increased risk for an adverse outcome (eligibility) or may result in
withdrawal from treatment (safety).
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CIRCADIAN VARIATION IN SYMPTOMS OF OSTEOARTHRITIS e
POSSIBLE MODIFICATION FROM TREATMENT WITH SEED AND
SHELL CONTAINING POWDER FROM ROSE-HIP
K. Winther, K. Marstrand. Inst. for Clinical Res., Frederiksberg C, Denmark
Purpose: Stiffness and pain from osteoarthritis (OA), is often more
pronounced in the morning than later in the day. When testing treat-
ment of OA symptoms this circadian variation is rarely recognized. The
aim of this study, therefore, was to evaluate the size of change in
stiffness and pain scores from early morning until noon in OA patients.
We also tested if the reduction in stiffness and in pain from treatment, if
any, was more pronounced in the morning than later in the day.
Methods: Stiffness and pain from osteoarthritis (OA), is often more
pronounced in the morning than later in the day. When testing treat-
ment of OA symptoms this circadian variation is rarely recognized. The
aim of this study, therefore, was to evaluate the size of change in
stiffness and pain scores from early morning until noon in OA patients.
We also tested if the reduction in stiffness and in pain from treatment, if
any, was more pronounced in the morning than later in the day.
Results: Morning values for stiffness, group A (placebo ﬁrst): 4.90
þ/-2.30 vs 3.95 þ/- 1.82 at noon, a drop of 20% (p<0.000). Pain insig-
niﬁcantly declined by 5%. Testing the A group after a further 3 month on
active therapy resulted in a similar pattern - a signiﬁcant drop in stiff-
ness comparing morning and noon (p<0.035) a drop but not signiﬁcant
in pain. Group B (active treatment ﬁrst - then placebo): morning stiff-
ness 4.56 þ/- 2.01 vs 3.68 þ/- 1.86 at noon. A drop of 20% (p<0.000).
Pain: 4.27 þ/- 2.06 in the morning vs 3.60 þ/- 1.80 at noon, a 16%
reduction (p<0.000). A similar pattern was seen testing after 3 month
placebo. Lumping groups together (n¼47) did not alter conclusions
(data not given). When the A group was tested in the morning, active
treatment resulted in a signiﬁcant reduction of 20% (p<0.002) when
compared to placebo. This reduction was 10% and still signiﬁcant when
testing at noon (p<0.037). The delta decline in stiffness in the morning
caused by active treatment was 0.95 þ/- 1.46 as compared to noon, 0.39
þ/- 0.97 (p<0.046). Active treatment reduced pain by 15.5% (p<0.013) in
the morning corresponding to a similar reduction at noon: 15.9%
(p<0.055). No signiﬁcant change comparing time of day. In the B group
(active ﬁrst) there were no signiﬁcant changes in any of the parameters
